Nelarabine
CURRENT LOCATION:
HOMEKey projects》Nelarabine

Nelarabine

Project NameNelarabine 

Registration Classification3.1

Formulations and specifications Infusion:50ml:250mg

IndicationsFor recurrent T -cell acute lymphoblastic leukemia (T-ALL) or T -cell lymphoma (T-LBL) after at least two kinds of therapeutic applications chemotherapy therapy.

Original Research CompanyGlaxoSmithKline 

ProgressHas been reported to the State Council , the admissibility number : CXHL1200588; CXHL1200589

Category :Cancer drug 

Links:

地址:北京市丰台区造甲街南里5号4A楼2层
电话:010-63716441 63717341 传真:010-63728443
COPYRIGHT (C) 2014 Beijing Mega Pharmaceutical Science and Technology Co.,ltd. ALL RIGHTS RESERVED
版权所有 北京满格医药科技有限公司 京ICP备12000952号